514 related articles for article (PubMed ID: 23810462)
21. New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy.
Poveda E; Tabernilla A
AIDS Rev; 2016; 18(1):55. PubMed ID: 27028272
[TBL] [Abstract][Full Text] [Related]
22. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
23. Current views on HIV-1 latency, persistence, and cure.
Melkova Z; Shankaran P; Madlenakova M; Bodor J
Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447
[TBL] [Abstract][Full Text] [Related]
24. Block-And-Lock: New Horizons for a Cure for HIV-1.
Moranguinho I; Valente ST
Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
[TBL] [Abstract][Full Text] [Related]
25. Reversal of Latency as Part of a Cure for HIV-1.
Rasmussen TA; Tolstrup M; Søgaard OS
Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
[TBL] [Abstract][Full Text] [Related]
26. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
[TBL] [Abstract][Full Text] [Related]
27. Targeting HIV latency: pharmacologic strategies toward eradication.
Xing S; Siliciano RF
Drug Discov Today; 2013 Jun; 18(11-12):541-51. PubMed ID: 23270785
[TBL] [Abstract][Full Text] [Related]
28. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
[TBL] [Abstract][Full Text] [Related]
29. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
[TBL] [Abstract][Full Text] [Related]
30. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor.
Lim H; Kim KC; Son J; Shin Y; Yoon CH; Kang C; Choi BS
Virus Res; 2017 Jan; 227():1-5. PubMed ID: 27677464
[TBL] [Abstract][Full Text] [Related]
31. Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists.
Macedo AB; Novis CL; Bosque A
Front Immunol; 2019; 10():2450. PubMed ID: 31681325
[TBL] [Abstract][Full Text] [Related]
32. Challenges and Promise of Human Immunodeficiency Virus Remission.
Li Y; Mohammadi A; Li JZ
J Infect Dis; 2021 Feb; 223(12 Suppl 2):4-12. PubMed ID: 33586773
[TBL] [Abstract][Full Text] [Related]
33. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Kim Y; Anderson JL; Lewin SR
Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.
Yang HC; Xing S; Shan L; O'Connell K; Dinoso J; Shen A; Zhou Y; Shrum CK; Han Y; Liu JO; Zhang H; Margolick JB; Siliciano RF
J Clin Invest; 2009 Nov; 119(11):3473-86. PubMed ID: 19805909
[TBL] [Abstract][Full Text] [Related]
35. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Darcis G; Berkhout B; Pasternak AO
Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
[TBL] [Abstract][Full Text] [Related]
36. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
Chandra PK; Gerlach SL; Wu C; Khurana N; Swientoniewski LT; Abdel-Mageed AB; Li J; Braun SE; Mondal D
Sci Rep; 2018 Oct; 8(1):14702. PubMed ID: 30279437
[TBL] [Abstract][Full Text] [Related]
38. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.
Siliciano RF
Top HIV Med; 2005; 13(3):96-100. PubMed ID: 16170226
[TBL] [Abstract][Full Text] [Related]
39. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
[TBL] [Abstract][Full Text] [Related]
40. Barriers to HIV Cure.
Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
